If the treatment wins FDA approval, its success will depend on pricing. Vera's rival, Otsuka Pharmaceutical, which earned an ...

As a result, Archer isn't making revenue yet and is burning through its cash. And despite a flurry of good news in 2025 -- ...

Rigetti's stock has been red-hot in the past two years as investors have been feeling bullish on the future for quantum ...

The company no longer has potential for upside anytime soon, believes one market professional familiar with it.